日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Fibroblast Activation Protein Alpha-Targeted Nanoparticles for Tumor Microenvironment Remodeling and Antitumor Therapy in Triple-Negative Breast Cancer.

成纤维细胞活化蛋白α靶向纳米颗粒用于三阴性乳腺癌肿瘤微环境重塑和抗肿瘤治疗。

期刊:Biomaterials Research
影响因子:9.6
doi:10.34133/bmr.0347
Lameirinhas Ana, Díez Paula, Hicke Francisco J, Ágreda-Roca Anna, Torres-Ruiz Sandra, Sánchez-Serrano Paloma, Tapia Marta, Lluch Ana, Bermejo Begoña, Cejalvo Juan Miguel, Martínez-Máñez Ramón, Eroles Pilar, Garrido-Cano Iris
乳腺癌
细胞生物学
成纤维细胞
肿瘤微环境
发表日期：2026
文献求助 收藏

TROP2-targeting antibody-drug conjugates in breast cancer and ovarian carcinoma: therapeutic advances and resistance mechanisms

TROP2靶向抗体药物偶联物在乳腺癌和卵巢癌中的应用：治疗进展和耐药机制

期刊:Cancer Drug Resistance
影响因子:5.2
doi:10.20517/cdr.2025.195
Eroles, Pilar; Dawid de Vera, María Teresa; Lago, Víctor
肿瘤
乳腺癌
肿瘤免疫
卵巢癌
发表日期：2026
文献求助 收藏

TROP2-targeting antibody–drug conjugates in breast cancer and ovarian carcinoma: therapeutic advances and resistance mechanisms

TROP2靶向抗体药物偶联物在乳腺癌和卵巢癌中的应用：治疗进展和耐药机制

期刊:Bacteriological Reviews
影响因子:
doi:10.1128/br.13.3.135-159.1949
Hammon, W M; Eroles, Pilar; Dawid de Vera, María Teresa; Lago, Víctor
肿瘤
肿瘤免疫
乳腺癌
卵巢癌
发表日期：2026
文献求助 收藏

miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies

miR-99a-5p通过COX-2/ABCG2轴调控三阴性乳腺癌的阿霉素耐药性：从发现到体内研究

期刊:Cancer Communications
影响因子:24.9
doi:10.1002/cac2.12352
Garrido-Cano, Iris; Adam-Artigues, Anna; Lameirinhas, Ana; Blandez, Juan F; Candela-Noguera, Vicente; Rojo, Federico; Zazo, Sandra; Madoz-Gúrpide, Juan; Lluch, Ana; Bermejo, Begoña; Sancenón, Felix; Cejalvo, Juan Miguel; Martínez-Máñez, Ramón; Eroles, Pilar
ABCG2
肿瘤
肿瘤免疫
信号转导
乳腺癌
发表日期：2022
文献求助 收藏

MicroRNAs as a clue to overcome breast cancer treatment resistance

微小RNA或可作为克服乳腺癌治疗耐药性的关键线索

期刊:Cancer and Metastasis Reviews
影响因子:8.7
doi:10.1007/s10555-021-09992-0
Garrido-Cano, Iris; Pattanayak, Birlipta; Adam-Artigues, Anna; Lameirinhas, Ana; Torres-Ruiz, Sandra; Tormo, Eduardo; Cervera, Raimundo; Eroles, Pilar
肿瘤
肿瘤免疫
乳腺癌
治疗耐药
发表日期：2022
文献求助 收藏

Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?

癌症患者使用μ-阿片受体拮抗剂：事实还是虚构？

期刊:Current Oncology Reports
影响因子:5
doi:10.1007/s11912-022-01295-z
Belltall, Amparo; Mazzinari, Guido; Diaz-Cambronero, Oscar; Eroles, Pilar; Argente Navarro, María Pilar
信号转导
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

Solid Tumor Opioid Receptor Expression and Oncologic Outcomes: Analysis of the Cancer Genome Atlas and Genotype Tissue Expression Project

实体瘤阿片受体表达与肿瘤学预后：癌症基因组图谱和基因型组织表达计划的分析

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2022.801411
Belltall, Amparo; Zúñiga-Trejos, Sheila; Garrido-Cano, Iris; Eroles, Pilar; Argente-Navarro, Maria Pilar; Buggy, Donal J; Díaz-Cambronero, Oscar; Mazzinari, Guido
信号转导
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3(VNTR) polymorphisms and gene co-expression

乳腺癌中昼夜节律PER3基因的功能：PER3(VNTR)多态性和基因共表达的种系和体细胞遗传学研究

期刊:NPJ Breast Cancer
影响因子:7.6
doi:10.1038/s41523-021-00329-2
Fores-Martos, Jaume; Cervera-Vidal, Raimundo; Sierra-Roca, Julia; Lozano-Asencio, Carlos; Fedele, Vita; Cornelissen, Sten; Edvarsen, Hege; Tadeo-Cervera, Irene; Eroles, Pilar; Lluch, Ana; Tabares-Seisdedos, Rafa; Falcó, Antonio; Van't Veer, Laura J; Schmidt, Marjanka; Quigley, David A; Børresen-Dale, Anne-Lise; Kristensen, Vessela N; Balmain, Allan; Climent, Joan
肿瘤
PER3
肿瘤免疫
乳腺癌
细胞生物学
发表日期：2021
文献求助 收藏

Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective

口服选择性雌激素受体降解剂（SERDs）作为一种新型乳腺癌疗法：临床视角下的现状与未来

期刊:International Journal of Molecular Sciences
影响因子:4.9
doi:10.3390/ijms22157812
Hernando, Cristina; Ortega-Morillo, Belén; Tapia, Marta; Moragón, Santiago; Martínez, María Teresa; Eroles, Pilar; Garrido-Cano, Iris; Adam-Artigues, Anna; Lluch, Ana; Bermejo, Begoña; Cejalvo, Juan Miguel
肿瘤
肿瘤免疫
信号转导
乳腺癌
免疫/内分泌
发表日期：2021
文献求助 收藏

The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models.

新型口服 mTORC1/2 抑制剂 TAK-228 可逆转 HER2 阳性乳腺癌模型中的曲妥珠单抗耐药性

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers13112778
Sanz-Álvarez Marta, Martín-Aparicio Ester, Luque Melani, Zazo Sandra, Martínez-Useros Javier, Eroles Pilar, Rovira Ana, Albanell Joan, Madoz-Gúrpide Juan, Rojo Federico
肿瘤
乳腺癌
mTOR
肿瘤免疫
发表日期：2021
文献求助 收藏